{"id":"W2589078008","doi":"10.1093/annonc/mdw376.01","title":"Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Durvalumab; Internal medicine; Cohort; Nausea; Oncology; Gastroenterology; Cancer; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008141634,0.0002190814,0.0005102866,0.0003448848,0.0001578498,0.0005894113,0.0003831787,0.000197931,0.001392552],"category_scores_gemma":[0.001261274,0.0001626094,0.0006905178,0.0004786017,0.0001109125,0.0004464722,0.0002420144,0.0005404526,0.0002820319],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007395408,"about_ca_system_score_gemma":0.0004079579,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002298561,"about_ca_topic_score_gemma":0.004338976,"domain_scores_codex":[0.9997035,0.00004597326,0.00003634475,0.00007299783,0.0001060071,0.00003512586],"domain_scores_gemma":[0.9991848,0.0001920612,0.0003039581,0.0001005559,0.0001215789,0.00009700549],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.02422813,0.0004662691,0.7574776,0.000299336,0.003222707,0.0005842732,0.0001635828,0.003012683,0.01372742,0.0003692192,0.01670606,0.1797427],"study_design_scores_gemma":[0.001532594,0.002529069,0.9729653,0.00005918747,0.002174642,0.001450094,0.00007012109,0.002206878,0.002843094,0.0002818957,0.01385308,0.00003395294],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9837325,0.003344059,0.0004047343,0.0003567875,0.00005150524,0.0000405436,0.009036181,0.00005108396,0.002982484],"genre_scores_gemma":[0.9830328,0.001239427,0.0003839383,0.0004203101,0.0000919149,0.00004213283,0.01377466,0.00001484596,0.001000026],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002298561,"threshold_uncertainty_score":0.005365789,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02391640026690077,"score_gpt":0.3244297351281284,"score_spread":0.3005133348612276,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}